Download Image
    
Share
  
Post
c19early.org
Colchicine for COVID-19
54 studies with >30,000 patients
Serious outcome risk
Colchicine
Control
Significantly lower risk for mortality, ICU, hospitalization, and recovery.
18% lower risk in 30 RCTs CI 7-28%
COVID-19 Colchicine studies · October 2026
Colchicine was adopted in 1 country. Recent:
Ma.
Covid Analysis Colchicine reduces COVID-19 risk: real-time meta-analysis of 54 studies (Version 67)
Significantly lower risk is seen for mortality, ICU admission, hospitalization, and recovery. 24 studies from 24 independent teams in 14 countries show significant benefit. Meta-analysis using the most serious outcome reported shows..
Sep 22
 Ak et al., Frontiers in Public Health, doi:10.3389/fpubh.2026.1907698 COVID-19 outcomes in patients with inflammatory rheumatic diseases: associations with disease subtypes, treatments, and vaccination status
Retrospective 1,024 patients with inflammatory rheumatic diseases in Turkey. Colchicine use was associated with lower hospitalization among the 347 COVID-19-positive patients in univariable analyses, however colchicine was not retained in..
Feb 23
 Ma et al., Elsevier BV, doi:10.2139/ssrn.6256797 MMP1 Serves as a Common Link and Drug Target Between Gout and Severe COVID-19 Infection
In silico study identifying MMP1 as a shared therapeutic target between gout and severe COVID-19, suggesting colchicine may exert anti-inflammatory effects via direct binding to MMP1.
Oct 20
2025
 Bassi et al., JAMA Internal Medicine, doi:10.1001/jamainternmed.2025.5408 Effectiveness of Colchicine for the Treatment of Long COVID
16% lower long COVID (p=0.01). RCT 346 long COVID patients in India, showing no significant difference in functional capacity, respiratory function, or inflammatory markers with colchicine.
Sep 2
2025
 Horby et al., medRxiv, doi:10.1101/2025.08.29.25334732 Long-term follow-up of treatment comparisons in RECOVERY: a randomised, open-label, platform trial for patients hospitalised with COVID-19
6-month followup of RECOVERY patients. Results are reported within the respective trials for each treatment.
Apr 15
2025
 Mitev, V., MDPI AG, doi:10.20944/preprints202504.1220.v1 Prevention and Treatment of COVID-19 and Influenza with Bromhexine and High Doses of Colchicine
Review of bromhexine and colchicine for COVID-19 and influenza prevention and treatment.
Aug 24
2024
 Duraníková et al., Journal of Clinical Medicine, doi:10.3390/jcm13175013 Prevalence and Risk Factors of Headache Associated with COVID-19
98% lower long COVID (p=1) and 28% improvement (p=1). Retrospective 295 hospitalized COVID-19 patients in Slovakia showing 35% prevalence of headache, of which 41% of patients had persistent headache 12-15 months after infection. Authors' analysis of long COVID headache is only for the subgr..
Aug 11
2024
 Van Tin et al., Cells, doi:10.3390/cells13161331 Spike Protein of SARS-CoV-2 Activates Cardiac Fibrogenesis through NLRP3 Inflammasomes and NF-κB Signaling
In vitro study showing that the SARS-CoV-2 spike protein can activate cardiac fibroblasts through ACE2-dependent mechanisms, leading to cardiac fibrosis via the NLRP3 inflammasome and NF-κB signaling pathways. The results suggest that COV..
May 28
2024
 Landi et al., Journal of Cardiovascular Medicine, doi:10.2459/JCM.0000000000001639 Edoxaban and/or colchicine for patients with coronavirus disease 2019 managed in the out-of-hospital setting (CONVINCE): a randomized clinical trial
4% higher hospitalization (p=0.98), 5% higher need for oxygen therapy (p=0.97), 40% improvement (p=0.97), and 11% improved viral clearance (p=0.77). Early terminated RCT with 14 colchicine, 13 edoxaban, 16 colchicine+edoxaban, and 16 control patients, showing no significant difference in outcomes with treatment up to 7 days after PCR diagnosis.
May 15
2024
 Gertner et al., Cureus, doi:10.7759/cureus.60364 Colchicine and/or Naltrexone for Hospitalized COVID-19 Patients Not Requiring High Levels of Ventilatory Support (COLTREXONE): A Prospective, Randomized, Open-Label Trial
65% lower ICU admission (p=0.11), 43% improved recovery (p=0.14), 34% lower need for oxygen therapy (p=0.34), and 20% shorter hospitalization (p=0.13). Open-label RCT 137 hospitalized COVID-19 patients, showing lower progression to ICU/step-down ICU and improved recovery with colchicine, both without statistical significance. The primary outcome was changed mid-trial due to the low numbe..
Apr 20
2024
 Elshiwy et al., BMC Pulmonary Medicine, doi:10.1186/s12890-024-03001-0 The role of colchicine in the management of COVID-19: a meta-analysis
65% lower mortality (p=0.01), 60% lower ventilation (p=0.09), 71% lower ICU admission (p=0.08), and 93% lower need for oxygen therapy (p<0.0001). Systematic review and meta-analysis of 8 studies (4 RCTs) involving 16,488 COVID-19 patients showed significantly lower mortality and need for oxygen therapy with colchicine.
Apr 13
2024
 Mondeshki et al., Cureus, doi:10.7759/cureus.58164 High-Dose Colchicine: Key Factor in the Treatment of Morbidly Obese COVID-19 Patients
Case series of 3 morbidly obese COVID-19 patients, 2 outpatients and 1 hospitalized, showing rapid recovery with a therapeutic regimen including high-dose colchicine (5 mg loading dose followed by 1-3 mg daily maintenance dose). Authors h..
Mar 19
2024
 Inokuchi et al., The Kurume Medical Journal, doi:10.2739/kurumemedj.MS7012003 Oral Colchicine and Low-Dose Aspirin Combination Therapy for Non-elderly, Non-severe, Early Time From Onset, Adult Outpatients with Coronavirus Disease 2019 (COVID-19) during “The Fifth Pandemic Wave” in Japan
67% lower hospitalization (p=0.55) and 24% improved recovery (p=0.72). RCT 38 low risk outpatients in Japan, showing no significant differences for colchicine and low-dose aspirin compared to loxoprofen. Hospitalization was lower, without statistical significance (4.3% vs. 13.3%, p=0.34). There were no criti..
Mar 6
2024
 Vaziri et al., Heliyon, doi:10.1016/j.heliyon.2024.e27373 Investigating efficacy of colchicine plus phenolic monoterpenes fraction as a potential treatment for patients diagnosed with COVID-19: A randomized controlled parallel clinical trial
81% lower mortality (p=0.03), 87% lower ICU admission (p=0.002), and 35% shorter hospitalization (p<0.0001). RCT 179 hospitalized COVID-19 patients showing lower mortality, ICU admission, and hospitalization duration with colchicine plus phenolic monoterpenes compared to standard care alone. The intervention group received 0.8 mg/day colchicine ..
Feb 29
2024
 Yadollahzadeh et al., Coronaviruses, doi:10.2174/0126667975271636231109051950 Colchicine with Infliximab Compared to Infliximab in Hospitalized Patients with COVID-19 Pneumonia: An Open-label Randomized Trial
33% lower mortality (p=0.54). Open-label RCT with 52 severe COVID-19 pneumonia patients showing no significant differences in mortality with colchicine. All patients received infliximab and remdesivir.
Dec 18
2023
 Mehrizi et al., Frontiers in Public Health, doi:10.3389/fpubh.2023.1280434 Drug prescription patterns and their association with mortality and hospitalization duration in COVID-19 patients: insights from big data
13% higher mortality (p<0.0001). Retrospective study of 917,198 hospitalized COVID-19 cases covered by the Iran Health Insurance Organization over 26 months showing that antithrombotics, corticosteroids, and antivirals reduced mortality while diuretics, antibiotics, and..
Oct 20
2023
 Mitev, V., Pharmacia, doi:10.3897/pharmacia.70.e112550 Comparison of treatment of COVID-19 with inhaled bromhexine, higher doses of colchicine and hymecromone with WHO-recommended paxlovid, molnupiravir, remdesivir, anti-IL-6 receptor antibodies and baricitinib
Review of treatment of COVID-19 with inhaled bromhexine, higher doses of colchicine and hymecromone compared to WHO-recommended paxlovid, molnupiravir, remdesivir, anti-IL-6 receptor antibodies, and baricitinib. The author argues that the..
Jun 13
2023
 Hassan et al., Research Square, doi:10.21203/rs.3.rs-3049708/v1 The effects of probiotic Lactobacillus acidophilus and colchicine on the control of symptoms, duration, and disease progression of mild and moderate cases of COVID-19: A randomized controlled clinical trial
40% higher hospitalization (p=0.76) and 4% improved recovery (p=1). RCT 150 patients in Egypt showing no significant difference in outcomes with colchicine. SOC included vitamin C, D, and zinc. Colchicine 0.5mg tid days 1-3, bid days 4-7.
May 17
2023
 Danjuma et al., Elsevier BV, doi:10.2139/ssrn.4447127 Does Colchicine Reduce Mortality in Patients with Covid-19 Clinical Syndrome? An Umbrella Review of Published Meta-Analyses
32% lower mortality (p<0.0001). Umbrella review of 18 colchicine meta analyses, showing significantly lower COVID-19 mortality with colchicine.
Mar 23
2023
 Villamañán et al., Eur. J. Hosp. Pharm., doi:10.1136/ejhpharm-2023-eahp.56 Targeting patients with pneumonia by COVID-19 that could be beneficiated by colchicine
42% lower mortality (p=0.03). Retrospective 111 hospitalized COVID-19 pneumonia patients treated with colchicine and 111 matched controls, showing lower mortality with colchicine treatment.
Mar 22
2023
 Chevalier et al., Frontiers in Medicine, doi:10.3389/fmed.2023.1152587 CovAID: Identification of factors associated with severe COVID-19 in patients with inflammatory rheumatism or autoimmune diseases
28% higher mortality (p=0.54) and 8% lower hospitalization (p=0.83). Retrospective 1,213 rheumatic disease patients in France, showing no significant difference with colchicine use in univariate analysis.
Feb 24
2023
 Shah et al., BMJ Open, doi:10.1136/bmjopen-2022-067910 Colchicine and high-intensity rosuvastatin in the treatment of non-critically ill patients hospitalised with COVID-19: a randomised clinical trial
75% higher mortality (p=0.54), 200% higher ventilation (p=0.28), and 46% higher severe cases (p=0.34). RCT 250 late stage (80% on oxygen) hospitalized patients in the USA, showing no significant differences with combined colchicine/rosuvastatin treatment. There was a trend towards increased risk, which authors note may be due to chance bec..
Jan 21
2023
 Sunil Naik et al., Contemporary Clinical Trials Communications, doi:10.1016/j.conctc.2023.101070 Effect of colchicine and aspirin given together in patients with moderate COVID-19
7% improved recovery (p=0.21). RCT 122 hospitalized patients in India, showing improved recovery with colchicine treatment. All patients received aspirin. There was one death and higher progression in the colchicine arm, however 3 patients in the colchicine arm had bas..
Jan 16
2023
 Kasiri et al., Journal of Investigative Medicine, doi:10.1177/10815589221141815 The effects of colchicine on hospitalized COVID-19 patients: A randomized, double-blind, placebo-controlled clinical trial
7% lower mortality (p=1), 7% lower ventilation (p=1), 24% higher ICU admission (p=0.63), and 28% improved recovery (p=0.59). Very late treatment (10 days from onset) RCT 110 patients in Iran, showing no significant difference in outcomes with colchicine. Colchicine 2mg loading dose followed by 0.5mg bid for 7 days.
Jan 13
2023
 Sáenz-Aldea et al., Journal of Medical Virology, doi:10.1002/jmv.28496 Colchicine and risk of hospitalisation due to COVID-19: a population-based study
8% higher hospitalization (p=0.68) and 12% more cases (p=0.68). Retrospective 86,652 patients in Spain, showing no significant difference in cases and hospitalization with colchicine use. The different risk for patients prescribed colchicine may not be fully adjusted for. See [onlinelibrary.wiley.com].
Dec 31
2022
 Haroon et al., Journal of Physiology and Pharmacology, doi:10.26402/jpp.2022.3.09 Colchicine anti-inflammatory therapy for non-intensive care unit hospitalized COVID-19 patients: results from a pilot open-label, randomized controlled clinical trial
34% improved recovery (p=0.11). Open-label RCT 96 hospitalized COVID-19 patients in Pakistan showing no significant difference in clinical outcomes with colchicine treatment, however baseline severity was not comparable - 85% vs. 56% had SpO2 <93 (p = 0.003), with the Q..
Dec 13
2022
 Hueda-Zavaleta et al., PeerJ, doi:10.7717/peerj.14290 Determination of PaO2/FiO2 after 24 h of invasive mechanical ventilation and ΔPaO2/FiO2 at 24 h as predictors of survival in patients diagnosed with ARDS due to COVID-19
33% higher mortality (p=0.33). Retrospective 200 patients with ARDS due to COVID-19 on invasive mechanical ventilation, showing no significant difference in mortality with colchicine treatment. The Cox proportional hazards result is from [journals.plos.org].
Nov 16
2022
 Rahman et al., PLOS ONE, doi:10.1371/journal.pone.0277790 Efficacy of colchicine in patients with moderate COVID-19: A double-blinded, randomized, placebo-controlled trial
71% lower mortality (p=0.04) and 71% lower progression (p=0.04). RCT 300 patients in Bangladesh, published 2 years after completion, showing significantly lower mortality with treatment at 28 days (not significant at 14 days). 1.2mg colchicine on day 1 followed by 0.6mg for 13 days.
Oct 31
2022
 Perricone et al., European Journal of Internal Medicine, doi:10.1016/j.ejim.2022.10.016 Treatment with COLchicine in hospitalized patients affected by COVID-19: the COLVID-19 trial
36% higher mortality (p=0.77), 7% higher progression (p=1), 76% lower ICU admission (p=0.21), and 4% shorter hospitalization (p=0.69). RCT 152 hospitalized patients in Italy, showing no significant difference in outcomes with colchicine treatment. Table 2 shows 13% of patients treated with antivirals in the colchicine arm, however 16.9% were treated with one specific ant..
Oct 10
2022
 Eikelboom et al., The Lancet Respiratory Medicine, doi:10.1016/S2213-2600(22)00299-5 Colchicine and aspirin in community patients with COVID-19 (ACT): an open-label, factorial, randomised, controlled trial
9% higher mortality (p=0.84), 2% higher combined mortality/hospitalization (p=0.93), and 2% higher hospitalization (p=0.92). Late (5.4 days) outpatient RCT showing no significant difference in outcomes with colchicine treatment. Authors include a meta analysis of 6 colchicine RCTs, however there were 19 RCTs as of the publication date [c19colchicine.com].
Oct 10
2022
 Eikelboom et al., The Lancet Respiratory Medicine, doi:10.1016/S2213-2600(22)00298-3 Colchicine and the combination of rivaroxaban and aspirin in patients hospitalised with COVID-19 (ACT): an open-label, factorial, randomised, controlled trial
8% higher mortality (p=0.38) and 4% higher progression (p=0.58). RCT very late stage (baseline SpO2 80%) patients, showing no significant differences with colchicine treatment.
Sep 29
2022
 Hernández-Rodríguez et al., Clinical Drug Investigation, doi:10.1007/s40261-022-01201-2 FRAGILE-COLCOVID19: A Clinical Trial Based on Early Administration of an Oral Combination of Colchicine and Prednisone in Elderly Patients with COVID-19 in Geriatric Facilities
16% higher mortality (p=1) and 42% improvement (p=0.25). RCT 54 elderly patients in Spain comparing colchicine + prednisone vs. dexamethasone, showing lower combined mortality/therapeutic failure with colchicine + prednisone, but no significant difference in mortality. Data appears unreliable, ..
Sep 19
2022
 Correa-Rodríguez et al., Medicina Clínica (English Edition), doi:10.1016/j.medcle.2022.08.009 Clinical course of Covid-19 in a cohort of patients with Behçet disease
150% higher need for oxygen therapy (p=1), 150% higher hospitalization (p=1), 7% improved recovery (p=1), and 1% fewer cases (p=1). Retrospective 244 Behçet disease patients in Spain, showing no significant difference in outcomes with colchicine treatment. Confounding by indication may significantly affect results - colchicine may be prescribed more often for more ser..
Jul 27
2022
 Rai et al., Journal of Advances in Medicine and Medical Research, doi:10.9734/jammr/2022/v34i2031503 The Potential Role of Colchicine in Reducing Mortality and Mechanical Ventilation Rates in COVID-19 Infection: A Meta-analysis
37% lower mortality (p=0.001). Meta analysis of 12 colchicine studies, showing significantly lower mortality with treatment.
Jul 21
2022
 Avanoglu Guler et al., Modern Rheumatology, doi:10.1093/mr/roac074 COVID-19 in familial Mediterranean fever: Clinical course and complications related to primary disease
79% lower need for oxygen therapy (p=0.04). Retrospective 73 familial Mediterranean fever patients with COVID-19 in Turkey, showing significantly higher risk of hospitalization for respiratory support with non-adherence to colchicine treatment before the infection.
Jun 29
2022
 Hunt et al., Journal of General Internal Medicine, doi:10.1007/s11606-022-07701-3 Medications Associated with Lower Mortality in a SARS-CoV-2 Positive Cohort of 26,508 Veterans
68% lower mortality (p=0.003). Retrospective 26,508 consecutive COVID+ veterans in the USA, showing lower mortality with multiple treatments including colchicine. Treatment was defined as drugs administered ≥50% of the time within 2 weeks post-COVID+, and may be a cont..
Jun 2
2022
 Cecconi et al., Scientific Reports, doi:10.1038/s41598-022-13424-6 Efficacy of short-course colchicine treatment in hospitalized patients with moderate to severe COVID-19 pneumonia and hyperinflammation: a randomized clinical trial
29% lower mortality (p=0.62), 50% lower ventilation (p=0.29), 21% lower ICU admission (p=0.67), and 15% improvement (p=0.62). RCT 240 hospitalized patients with COVID-19 pneumonia, mean 9 days from the onset of symptoms, showing no significant differences with colchicine treatment. EudraCT 2020-001841-38.
May 5
2022
 Jalal et al., Indian Journal of Rheumatology, doi:10.4103/injr.injr_264_21 Effectiveness of colchicine among patients with COVID-19 infection: A randomized, open-labeled, clinical trial
24% shorter hospitalization (p=0.009). Open label RCT of colchicine showing improved recovery with treatment. Only the abstract is currently available. Colchicine 0.5mg bid for 14 days.
Apr 28
2022
 Pimenta Bonifácio et al., Revista da Sociedade Brasileira de Medicina Tropical, doi:10.1590/0037-8682-0565-2022 (date from preprint) Efficacy and safety of Ixekizumab vs. low-dose IL-2 vs. Colchicine vs. standard of care in the treatment of patients hospitalized with moderate-to-critical COVID-19: A pilot randomized clinical trial (STRUCK: Survival Trial Using Cytokine Inhibitors)
85% greater improvement (p=0.23). Open label RCT late stage hospitalized patients in Brazil with 14 colchicine and 16 SOC patients, showing lower mortality and improved recovery with treatment, without statistical significance. Authors note that the colchicine group had o..
Apr 12
2022
 Gorial et al., Annals of Medicine and Surgery, doi:10.1016/j.amsu.2022.103593 Randomized controlled trial of colchicine add on to the standard therapy in moderate and severe corona virus Disease-19 infection
63% improved recovery (p=0.001). RCT with 80 colchicine and 80 control patients, showing improved recovery with treatment. SOC included vitamin C, vitamin D, and zinc.
Apr 5
2022
 Yasmin et al., PLOS ONE, doi:10.1371/journal.pone.0266245 Safety and efficacy of colchicine in COVID-19 patients: A systematic review and meta-analysis of randomized control trials
Meta analysis of 5 colchicine RCTs (currently there are RCTs) finding that treatment significantly reduced COVID-19 severity.
Mar 21
2022
 Oztas et al., Journal of Medical Virology, doi:10.1002/jmv.27731 Frequency and Severity of COVID-19 in Patients with Various Rheumatic Diseases Treated Regularly with Colchicine or Hydroxychloroquine
406% higher hospitalization (p=0.12), 73% more symptomatic cases (p=0.07), and 24% more cases (p=0.35). Retrospective 635 HCQ users and 643 household contacts, showing higher risk with colchicine in unadjusted results. Patients with conditions leading to the use of colchicine may have significantly different baseline risk, e.g. [Topless].
Feb 2
2022
 Pourdowlat et al., Phytotherapy Research, doi:10.1002/ptr.7319 Efficacy and safety of colchicine treatment in patients with COVID-19: A prospective, multicenter, randomized clinical trial
73% lower hospitalization (p=0.004) and 38% improved recovery (p=0.03). RCT 202 patients in Iran, 102 treated with colchicine, showing lower hospitalization and improved clinical outcomes with treatment.
Jan 31
2022
 Karakaş et al., The Journal of Infection in Developing Countries, doi:10.3855/jidc.14924 Reducing length of hospital stay with colchicine
13% lower mortality (p=0.72), 16% lower ICU admission (p=0.5), and 25% shorter hospitalization (p=0.0001). Retrospective 356 hospitalized COVID-19 patients, shorter hospitalization time with colchicine treatment. There were no statistically significant differences for mortality or ICU admission. Significantly lower mortality was seen with high..
Jan 28
2022
 Topless et al., The Lancet Rheumatology, doi:10.1016/S2665-9913(21)00401-X Gout and the risk of COVID-19 diagnosis and death in the UK Biobank: a population-based study
23% lower mortality (p=0.12). UK Biobank retrospective showing a higher risk of COVID-19 cases and mortality for patients with gout. Among patients with gout, mortality risk was lower for those on colchicine, OR 1.06 [0.60-1.89], compared to those without colchicine, ..
Jan 12
2022
 Zein et al., Diabetes & Metabolic Syndrome: Clinical Research & Reviews, doi:10.1016/j.dsx.2022.102395 Effect of colchicine on mortality in patients with COVID-19 – A systematic review and meta-analysis
Systematic review and meta analysis showing that colchicine was associated with lower mortality in COVID-19 patients: All studies: RR 0.66 [95%CI 0.53, 0.83], p < 0.001; I2: 42% RCTs: RR 0.81 [95%CI 0.54, 1.20], p = 0.29; I2: 10% The RCT ..
Jan 8
2022
 Monserrat Villatoro et al., Pharmaceuticals, doi:10.3390/ph15010078 A Case-Control of Patients with COVID-19 to Explore the Association of Previous Hospitalisation Use of Medication on the Mortality of COVID-19 Disease: A Propensity Score Matching Analysis
80% lower mortality (p=0.02). PSM retrospective 3,712 hospitalized patients in Spain, showing lower mortality with existing use of azithromycin, bemiparine, budesonide-formoterol fumarate, cefuroxime, colchicine, enoxaparin, ipratropium bromide, loratadine, mepyramine..
Dec 31
2021
 Alsultan et al., Interdisciplinary Perspectives on Infectious Diseases, doi:10.1155/2021/2129006 Efficacy of Colchicine and Budesonide in Improvement Outcomes of Patients with Coronavirus Infection 2019 in Damascus, Syria: A Randomized Control Trial
36% lower mortality (p=0.7) and 20% shorter hospitalization. Small RCT 49 severe condition hospitalized patients in Syria, showing lower mortality with colchicine and shorter hospitalization time with both colchicine and budesonide (all of these were not statistically significant).
Dec 30
2021
 Kow et al., Immunity, Inflammation and Disease, doi:10.1002/iid3.562 The effect of colchicine on mortality outcome and duration of hospital stay in patients with COVID‐19: A meta‐analysis of randomized trials
Meta-analysis of 10 randomized controlled trials with 17,976 COVID-19 patients showing significantly shorter hospitalization with colchicine treatment. Mortality was lower but without statistical significance.
Dec 29
2021
 Diaz et al., JAMA Network Open, doi:10.1001/jamanetworkopen.2021.41328 Effect of Colchicine vs Usual Care Alone on Intubation and 28-Day Mortality in Patients Hospitalized With COVID-19
12% lower mortality (p=0.3) and 17% lower combined mortality/intubation (p=0.08). Very late stage RCT (O2 88%, 84% on oxygen) with 1,279 hospitalized patients in Argentina, showing lower mortality and lower combined mortality/ventilation, statistically significant only for the combined outcome and per-protocol analysis..
Nov 25
2021
 Ozcifci et al., Rheumatology International, doi:10.1007/s00296-021-05056-2 The incidence, clinical characteristics, and outcome of COVID-19 in a prospectively followed cohort of patients with Behçet’s syndrome
4% fewer cases (p=0.72). Prospective analysis of 1,047 Behçet’s syndrome patients in Turkey, showing no significant difference in cases with colchicine use.
Nov 9
2021
 Absalón-Aguilar et al., Journal of General Internal Medicine, doi:10.1007/s11606-021-07203-8 Colchicine Is Safe Though Ineffective in the Treatment of Severe COVID-19: a Randomized Clinical Trial (COLCHIVID)
29% lower mortality (p=0.74), 17% lower progression (p=0.67), and 13% worse recovery (p=0.59). Very late stage RCT with 56 colchicine and 60 control patients in Mexico, showing no significant differences.
Sep 23
2021
 Dorward et al., British Journal of General Practice, doi:10.3399/BJGP.2022.0083 (date from preprint) Colchicine for COVID-19 in the community (PRINCIPLE): a randomised, controlled, adaptive platform trial
70% lower mortality (p=0.43), 30% higher combined mortality/hospitalization (p=0.66), and 6% worse recovery (p=0.67). Late treatment RCT with 156 colchicine patients in the UK, showing no significant differences. c19 early .org PRINCIPLE trial selective reporting delays Results for effective but politically inconvenient treatments were withheld for very ..
Sep 11
2021
 Pascual-Figal et al., International Journal of General Medicine, doi:10.2147/IJGM.S329810 Colchicine in Recently Hospitalized Patients with COVID-19: A Randomized Controlled Trial (COL-COVID)
80% lower mortality (p=0.24), 80% lower ventilation (p=0.24), 87% improved 7-point scale results (p=0.03), and 15% longer hospitalization (p=0.34). RCT with 52 colchicine patients and 51 control patients, showing lower risk of clinical deterioration with treatment. COL-COVID. NCT04350320.
Aug 23
2021
 Lien et al., Life, doi:10.3390/life11080864 Repurposing Colchicine in Treating Patients with COVID-19: A Systematic Review and Meta-Analysis
43% lower mortality (p=0.008) and 33% lower ventilation (p=0.15). Meta analysis of 11 colchicine studies showing significantly lower mortality with treatment.
Jul 18
2021
 Elshafei et al., European Journal of Clinical Investigation, doi:10.1111/eci.13645 Colchicine use might be associated with lower mortality in COVID‐19 patients: A meta‐analysis
65% lower mortality (p<0.0001). Meta analysis of 9 colchicine studies showing significantly lower mortality with treatment.
Jul 10
2021
 Gaitán-Duarte et al., eClinicalMedicine, doi:10.1016/j.eclinm.2021.101242 Effectiveness of rosuvastatin plus colchicine, emtricitabine/tenofovir and combinations thereof in hospitalized patients with COVID-19: a pragmatic, open-label randomized trial
22% lower mortality (p=0.38). RCT 633 hospitalized patients in Colombia, 153 treated with colchicine + rosuvastatin, 160 treated with emtricitabine + tenofovir, and 159 treated with the combination of both regimens. Statistically significant improvement was seen only ..
Jul 10
2021
 Golpour et al., International Journal of Immunopathology and Pharmacology, doi:10.1177/20587384211031763 The effectiveness of Colchicine as an anti-inflammatory drug in the treatment of coronavirus disease 2019: Meta-analysis
36% lower mortality (p<0.0001). Meta analysis of 10 studies showing significantly lower COVID-19 mortality with colchicine.
Jun 30
2021
 Kevorkian et al., Journal of Infection, doi:10.1016/j.jinf.2021.02.008 Oral corticoid, aspirin, anticoagulant, colchicine, and furosemide to improve the outcome of hospitalized COVID-19 patients - the COCAA-COLA cohort study
96% lower progression (p=0.0005). Observational study in France with 28 hospitalized patients treated with prednisone/furosemide/colchicine/salicylate/direct anti-Xa inhibitor, and 40 control patients, showing lower combined mortality, ventilation, or high-flow oxygen the..
Jun 18
2021
 Hayward et al., BMJ Open, doi:10.1136/bmjopen-2020-046799 Platform Randomised trial of INterventions against COVID-19 In older peoPLE (PRINCIPLE): protocol for a randomised, controlled, open-label, adaptive platform, trial of community treatment of COVID-19 syndromic illness in people at higher risk
Protocol paper for the PRINCIPLE trial. For the colchicine arm see [Dorward], for budesonide see [Yu], and for ivermectin see [Hayward].
Jun 10
2021
 Hueda-Zavaleta et al., Revista Peruana de Medicina Experimental y Salud Pública, doi:10.17843/rpmesp.2021.382.7158 Factores asociados a la muerte por COVID-19 en pacientes admitidos en un hospital público en Tacna, Perú
54% lower mortality (p=0.03). Retrospective 450 late stage (median oxygen saturation 86%) COVID+ hospitalized patients in Peru, showing lower mortality with colchicine treatment.
May 18
2021
 Horby et al., The Lancet Respiratory Medicine, doi:10.1016/S2213-2600(21)00435-5 (date from preprint) Colchicine in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial
1% higher mortality (p=0.85), 18% higher ventilation (p=0.06), 2% higher combined mortality/intubation (p=0.47), and 2% lower hospital discharge (p=0.44). RCT with 5,610 colchicine and 5,730 control patients showing mortality RR 1.01 [0.93-1.10]. Very late stage treatment, median 9 days after symptom onset, baseline 32% ventilation (5% invasive). ISRCTN 50189673. 6-month results are from [..
Apr 30
2021
 Salah et al., The American Journal of Cardiology, doi:10.1016/j.amjcard.2021.02.005 Meta-analysis of the Effect of Colchicine on Mortality and Mechanical Ventilation in COVID-19
38% lower mortality (p=0.0004) and 25% lower ventilation (p=0.27). Meta analysis of 8 studies, showing significantly lower COVID-19 mortality with colchicine.
Mar 24
2021
 Manenti et al., PLOS ONE, doi:10.1371/journal.pone.0248276 Reduced mortality in COVID-19 patients treated with colchicine: Results from a retrospective, observational study
76% lower mortality (p=0.005) and 44% improved recovery (p=0.05). IPTW retrospective 141 COVID-19 patients (83% hospitalized), 71 treated with colchicine and 70 matched control patients, showing lower mortality and faster recovery with treatment.
Mar 14
2021
 Hariyanto et al., Clinical and Experimental Pharmacology and Physiology, doi:10.1111/1440-1681.13488 Colchicine treatment can improve outcomes of coronavirus disease 2019 (COVID-19): A systematic review and meta-analysis
Meta analysis concluding that colchicine can reduce severity and mortality in COVID-19 patients, mortality OR 0.43 [0.32-0.58].
Mar 6
2021
 García-Posada et al., Journal of Infection and Public Health, doi:10.1016/j.jiph.2021.02.013 Clinical outcomes of patients hospitalized for COVID-19 and evidence-based on the pharmacological management reduce mortality in a region of the Colombian Caribbean
57% lower mortality (p=0.01). Retrospective 209 hospitalized patients in Colombia, showing lower mortality with antibiotics + LMWH + corticosteroids + colchicine in multivariable analysis.
Feb 28
2021
 Mareev et al., Kardiologiia, doi:10.18087/cardio.2021.2.n1560 Proactive anti-inflammatory therapy with colchicine in the treatment of advanced stages of new coronavirus infection. The first results of the COLORIT study
50% improved recovery (p=0.06) and 26% shorter hospitalization (p=0.08). Small trial with 21 colchicine patients and 22 control patients in Russia, showing improved recovery with treatment. The trial was originally an RCT, however randomization to the control arm was stopped after 5 patients, and 17 retrospect..
Jan 31
2021
 Madrid-García et al., Therapeutic Advances in Musculoskeletal Disease, doi:10.1177/1759720x211002684 Influence of colchicine prescription in COVID-19-related hospital admissions: a survival analysis
37% higher mortality (p=0.57) and 137% higher hospitalization (p=0.2). Retrospective 9,379 patients attending a rheumatology outpatient clinic in Spain, showing higher mortality and hospitalization with colchicine use, without statistical significance.
Jan 27
2021
 Tardif et al., The Lancet Respiratory Medicine, doi:10.1016/S2213-2600(21)00222-8 (date from preprint) Colchicine for community-treated patients with COVID-19 (COLCORONA): a phase 3, randomised, double-blinded, adaptive, placebo-controlled, multicentre trial
44% lower mortality (p=0.3), 20% lower combined mortality/hospitalization (p=0.08), 47% lower ventilation (p=0.09), and 20% lower hospitalization (p=0.09). RCT for relatively low risk outpatients, 2235 treated with colchicine a mean of 5.3 days after the onset of symptoms, and 2253 controls, showing lower mortality, ventilation, and hospitalization with treatment. This study was submitted to..
Jan 7
2021
 Valerio Pascua et al., PLOS ONE, doi:10.1371/journal.pone.0245025 A multi-mechanism approach reduces length of stay in the ICU for severe COVID-19 patients
23% lower mortality (p=0.6) and 40% shorter ICU admission (p=0.03). Retrospective 65 ICU patients in the USA and Honduras, showing shorter ICU stay with combined treatment including colchicine, LMWH, tocilizumab, dexamethasone, and methylprednisolone.
Dec 31
2020
 Mahale et al., Indian Journal of Critical Care Medicine, doi:10.5005/jp-journals-10071-23599 A Retrospective Observational Study of Hypoxic COVID-19 Patients Treated with Immunomodulatory Drugs in a Tertiary Care Hospital
7% higher mortality (p=0.83). Retrospective 134 hospitalized COVID-19 patients in India, showing no significant difference with colchicine treatment in unadjusted results.
Nov 5
2020
 Rodriguez-Nava et al., Mayo Clinic Proceedings: Innovations, Quality & Outcomes, doi:10.1016/j.mayocpiqo.2020.10.007 Clinical characteristics and risk factors for mortality of hospitalized patients with COVID-19 in a community hospital: A retrospective cohort study
6% lower mortality (p=0.87). Retrospective 313 patients, mostly critical stage and mostly requiring respiratory support. Confounding by indication likely.
Oct 27
2020
 Sandhu et al., Canadian Journal of Infectious Diseases and Medical Microbiology, doi:10.1155/2020/8865954 A Case Control Study to Evaluate the Impact of Colchicine on Patients Admitted to the Hospital with Moderate to Severe COVID-19 Infection
42% lower mortality (p=0.0006), 53% lower ventilation (p<0.0001), 42% higher hospital discharge (p=0.0006), and 5% shorter hospitalization. Prospective cohort study of hospitalized patients in the USA, 34 treated with colchicine, showing lower mortality and intubation with treatment.
Oct 23
2020
 Pinzón et al., Research Square, doi:10.21203/rs.3.rs-94922/v1 Clinical Outcome of Patients with COVID-19 Pneumonia Treated with Corticosteroids and Colchicine in Colombia
35% lower mortality (p=0.18). Retrospective 301 pneumonia patients in Colombia showing lower mortality with colchicine treatment.
Sep 21
2020
 Salehzadeh et al., Mediterranean Journal of Rheumatology, doi:10.31138/mjr.33.2.232 (date from preprint) The Impact of Colchicine on COVID-19 patients: A Clinical Trial Study
23% shorter hospitalization (p=0.001). Open label RCT with 100 hospitalized patients in Iran, 50 treated with colchicine, showing shorter hospitalization time with treatment. There were no deaths.
Sep 14
2020
 Scarsi et al., Annals of the Rheumatic Diseases, doi:10.1136/annrheumdis-2020-217712 Association between treatment with colchicine and improved survival in a single-centre cohort of adult hospitalised patients with COVID-19 pneumonia and acute respiratory distress syndrome
85% lower mortality (p<0.0001). Retrospective 122 colchicine patients and 140 control patients in Italy, showing lower mortality with treatment. Confounding may be significant: the groups were recruited during different time periods of a rapidly evolving epidemic - the ..
Sep 14
2020
 Brunetti et al., Journal of Clinical Medicine, doi:10.3390/jcm9092961 Colchicine to Weather the Cytokine Storm in Hospitalized Patients with COVID-19
73% lower mortality (p=0.03) and 73% higher hospital discharge (p=0.03). PSM matched analysis from consecutive hospitalized patients, with 33 colchicine and 33 control matched patients, showing lower mortality with treatment.
Aug 12
2020
 Lopes et al., RMD Open, doi:10.1136/rmdopen-2020-001455 (date from preprint) Beneficial effects of colchicine for moderate to severe COVID-19: a randomised, double-blinded, placebo-controlled clinical trial
22% shorter hospitalization (p=0.01). RCT with 36 colchicine and 36 control patients, showing reduced length of hospitalization and oxygen therapy with treatment.
Jun 24
2020
 Deftereos et al., JAMA Network Open, doi:10.1001/jamanetworkopen.2020.13136 Effect of Colchicine vs Standard Care on Cardiac and Inflammatory Biomarkers and Clinical Outcomes in Patients Hospitalized With Coronavirus Disease 2019: The GRECCO-19 Randomized Clinical Trial
77% lower mortality (p=0.19), 82% lower ventilation (p=0.1), and 87% lower progression (p=0.05). RCT with 55 patients treated with colchicine and 50 control patients, showing lower mortality and ventilation with treatment.